Biomarin Pharmaceutical (FRA:BM8) Accounts Payable & Accrued Expense : €546 Mil (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Accounts Payable & Accrued Expense?

Biomarin Pharmaceutical's quarterly accounts payable & accrued expense declined from Sep. 2023 (€445 Mil) to Dec. 2023 (€399 Mil) but then increased from Dec. 2023 (€399 Mil) to Mar. 2024 (€546 Mil).

Biomarin Pharmaceutical's annual accounts payable & accrued expense increased from Dec. 2021 (€239 Mil) to Dec. 2022 (€323 Mil) and increased from Dec. 2022 (€323 Mil) to Dec. 2023 (€399 Mil).

Biomarin Pharmaceutical Accounts Payable & Accrued Expense Historical Data

The historical data trend for Biomarin Pharmaceutical's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Accounts Payable & Accrued Expense Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

309.57

244.81

239.07

322.56

398.74

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															409.70	411.61	444.83	398.74	546.06

Biomarin Pharmaceutical Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Biomarin Pharmaceutical (FRA:BM8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (FRA:BM8) Headlines

No Headlines